These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 21466589)

  • 1. Treatment of vitiligo with narrowband-UVB (TL01) combined with tacrolimus ointment (0.1%) vs. placebo ointment, a randomized right/left double-blind comparative study.
    Nordal EJ; Guleng GE; Rönnevig JR
    J Eur Acad Dermatol Venereol; 2011 Dec; 25(12):1440-3. PubMed ID: 21466589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does topical tacrolimus ointment enhance the efficacy of narrowband ultraviolet B therapy in vitiligo? A left-right comparison study.
    Majid I
    Photodermatol Photoimmunol Photomed; 2010 Oct; 26(5):230-4. PubMed ID: 20831696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Narrow-band UVB phototherapy combined with tacrolimus ointment in vitiligo: a review of 110 patients.
    Fai D; Cassano N; Vena GA
    J Eur Acad Dermatol Venereol; 2007 Aug; 21(7):916-20. PubMed ID: 17659000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An open randomized study to compare narrow band UVB, topical pimecrolimus and topical tacrolimus in the treatment of vitiligo.
    Stinco G; Piccirillo F; Forcione M; Valent F; Patrone P
    Eur J Dermatol; 2009; 19(6):588-93. PubMed ID: 19651562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response of vitiligo to once- vs. twice-daily topical tacrolimus: a controlled prospective, randomized, observer-blinded trial.
    Radakovic S; Breier-Maly J; Konschitzky R; Kittler H; Sator P; Hoenigsmann H; Tanew A
    J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):951-3. PubMed ID: 19496898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy of pimecrolimus 1% cream plus narrow-band ultraviolet B in the treatment of vitiligo: a double-blind, placebo-controlled clinical trial.
    Esfandiarpour I; Ekhlasi A; Farajzadeh S; Shamsadini S
    J Dermatolog Treat; 2009; 20(1):14-8. PubMed ID: 18608735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vitiligo, NB-UVB and tacrolimus: our experience in Naples.
    Baldo A; Lodi G; Di Caterino P; Monfrecola G
    G Ital Dermatol Venereol; 2014 Feb; 149(1):123-30. PubMed ID: 24566573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, placebo-controlled, double-blind trial comparing narrowband UV-B Plus 0.1% tacrolimus ointment with narrowband UV-B plus placebo in the treatment of generalized vitiligo.
    Mehrabi D; Pandya AG
    Arch Dermatol; 2006 Jul; 142(7):927-9. PubMed ID: 16847214
    [No Abstract]   [Full Text] [Related]  

  • 9. Randomized double-blind trial of treatment of vitiligo: efficacy of psoralen-UV-A therapy vs Narrowband-UV-B therapy.
    Yones SS; Palmer RA; Garibaldinos TM; Hawk JL
    Arch Dermatol; 2007 May; 143(5):578-84. PubMed ID: 17519217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Topical calcipotriene and narrowband ultraviolet B in the treatment of vitiligo.
    Kullavanijaya P; Lim HW
    Photodermatol Photoimmunol Photomed; 2004 Oct; 20(5):248-51. PubMed ID: 15379875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topical tacrolimus and the 308-nm excimer laser: a synergistic combination for the treatment of vitiligo.
    Passeron T; Ostovari N; Zakaria W; Fontas E; Larrouy JC; Lacour JP; Ortonne JP
    Arch Dermatol; 2004 Sep; 140(9):1065-9. PubMed ID: 15381545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multicentre, randomized, double-blind, controlled study of long-term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitis.
    Reitamo S; Ortonne JP; Sand C; Cambazard F; Bieber T; Fölster-Holst R; Vena G; Bos JD; Fabbri P; Groenhoej Larsen C;
    Br J Dermatol; 2005 Jun; 152(6):1282-9. PubMed ID: 15948994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antioxidants and narrow band-UVB in the treatment of vitiligo: a double-blind placebo controlled trial.
    Dell'Anna ML; Mastrofrancesco A; Sala R; Venturini M; Ottaviani M; Vidolin AP; Leone G; Calzavara PG; Westerhof W; Picardo M
    Clin Exp Dermatol; 2007 Nov; 32(6):631-6. PubMed ID: 17953631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of vitiligo vulgaris with narrow-band UVB and oral Polypodium leucotomos extract: a randomized double-blind placebo-controlled study.
    Middelkamp-Hup MA; Bos JD; Rius-Diaz F; Gonzalez S; Westerhof W
    J Eur Acad Dermatol Venereol; 2007 Aug; 21(7):942-50. PubMed ID: 17659004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, double-blinded, placebo-controlled trial of pseudocatalase cream and narrowband ultraviolet B in the treatment of vitiligo.
    Bakis-Petsoglou S; Le Guay JL; Wittal R
    Br J Dermatol; 2009 Oct; 161(4):910-7. PubMed ID: 19523170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Occlusive treatment enhances efficacy of tacrolimus 0.1% ointment in adult patients with vitiligo: results of a placebo-controlled 12-month prospective study.
    Hartmann A; Bröcker EB; Hamm H
    Acta Derm Venereol; 2008; 88(5):474-9. PubMed ID: 18779885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 0.03% Tacrolimus ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis: results of a randomized double-blind controlled trial.
    Reitamo S; Harper J; Bos JD; Cambazard F; Bruijnzeel-Koomen C; Valk P; Smith C; Moss C; Dobozy A; Palatsi R;
    Br J Dermatol; 2004 Mar; 150(3):554-62. PubMed ID: 15030341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A double-blind, randomized, placebo-controlled trial of topical tacrolimus 0·1% vs. clobetasol propionate 0·05% in childhood vitiligo.
    Ho N; Pope E; Weinstein M; Greenberg S; Webster C; Krafchik BR
    Br J Dermatol; 2011 Sep; 165(3):626-32. PubMed ID: 21457214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Narrow-band UVB311 nm vs. broad-band UVB therapy in combination with topical calcipotriol vs. placebo in vitiligo.
    Hartmann A; Lurz C; Hamm H; Bröcker EB; Hofmann UB
    Int J Dermatol; 2005 Sep; 44(9):736-42. PubMed ID: 16135141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tacalcitol and narrow-band phototherapy in patients with vitiligo.
    Leone G; Pacifico A; Iacovelli P; Paro Vidolin A; Picardo M
    Clin Exp Dermatol; 2006 Mar; 31(2):200-5. PubMed ID: 16487090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.